Global Congenital Hyperinsulinism Treatment Market”- Forecast to 2030, Global Congenital Hyperinsulinism Treatment Market, by Disease Type (KATP-HI, GDH-HI, GK-HI, Other (SCHAD HI,HNF4A/HNF1A, etc.)), by Drug Type (Diazoxide, Octreotide, Glucagon, Nifedipine, Other (Sirolimus, Chlorothiazide, etc.), by Route of Administration (Oral, Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 206.0 Million in 2022 and is expected to exhibit a CAGR of 5.7% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing research and development activities by the key players in the market is expected to drive the global congenital hyperinsulinism treatment market growth. For instance, in September 2022, Zealand Pharma A/S, a biotechnology company announced that the clinical results from phase-3 trial of Dasiglucagon for treatment of congenital hyperinsulinism for newborns. Investigation was carried out for chronic dasiglucagon infusion, to prevent hypoglycemia in newly diagnosed children with congenital hyperinsulinism. Dasiglucagon is a glucagon analog that is suitable for administration via chronic subcutaneous infusion. In 2017, both the U.S. Food and Drug Administration (FDA) and the European Commission granted orphan drug designation for dasiglucagon for the treatment of CHI.
Global Congenital Hyperinsulinism Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a negative impact on the global congenital hyperinsulinism treatment market, owing to decrease in diagnosis of congenital hyperinsulinism and limited data availability of the drugs and the patients of congenital hyperinsulinism. For instance, according to the data published by the American Diabetes Association in October 2021, COVID-19 pandemic had compromised with data on long-term outcomes of people with Hypoglycemia. New-onset diabetes with SARS-CoV-2 infection also appears to be a complex syndrome associated with a number of pathophysiological mechanisms and, given we are still in the midst of a global COVID-19 pandemic, are likely to see even larger numbers of people globally with new-onset of hyperinsulinism. The pandemic had negatively impacted treatments of many Endocrinal diseases like diabetes, hypertension, hyperinsulinism and their funding opportunities. Furthermore, the measures implemented to avoid spread of COVID-19 had negatively impacted supply disruption and the decline in the international trade resulted from the COVID-19 pandemic also lead to lack of supply of essential drugs for endocrinal diseases.
Global Congenital Hyperinsulinism Treatment Market: Key Developments
New technique 18F-6-Fluoro-l-Dopa PET/CT Imaging has showed positive results in the diagnosis of congenital hyperinsulinism. For Instance, according to the data published by the National Center for the biotechnology information in July 2021, the new technique 18F-6-Fluoro-l-Dopa PET/CT Imaging for treatment has given promising results in the diagnosis of congenital hyperinsulinism. In these study of congenital hyperinsulinism treatment 18F-6-Fluoro-l-Dopa PET/CT Imaging is the effective method of choice for detection and localization of focal lesions of hyperinsulinism and is said to safe and adopted method as a standard of care in cases of HI with a suspected focal lesion.
Browse 45 Market Data Tables and 38 Figures spread through 190 Pages and in-depth TOC on “Global Congenital Hyperinsulinism Treatment Market”- Forecast to 2030, Global Congenital Hyperinsulinism Treatment Market, by Disease Type (KATP-HI, GDH-HI, GK-HI, Other (SCHAD HI, HNF4A/HNF1A,etc)), by Drug Type (Diazoxide, Octreotide, Glucagon, Nifedipine, Other (Sirolimus, Chlorothizide, etc.), by Route of Administration (Oral, Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
Key Takeaways of the Global Congenital Hyperinsulinism Treatment Market:
- The global congenital hyperinsulinism treatment market is expected to exhibit a CAGR of 5.7% during the forecast period due to the increasing research and development by the key players in the market. For instance, in July 2022, Rezolute, Inc., biopharmaceutical company, presented Positive Phase 2 data for RZ358, a drug for congenital hyperinsulinism. The clinical trial study for candidate RZ358, an intravenously administered human monoclonal antibody that binds to unique site (allosteric) on the insulin receptor throughout the body. The antibody modifies insulin’s binding and signaling to maintain the glucose levels in a normal range which counteracts the effects of elevated insulin in the body.
- Among drug type, diazoxide segment is estimated to hold a dominant position in the global congenital hyperinsulinism treatment market over the forecast period. For instance, according to the data published by the Frontiers in Endocrinology Journal in October 2020, the new possible strategies for the treatment of congenital hyperinsulinism includes effects of Diazoxide on the human islets cell clusters, the pancreas containing clusters of cells that produce hormones, this Diazoxide are the K-ATP channel openers which plays important role as the couple cellular metabolism in the pancreatic Beta cells. After the treatments the patients are in principle function and thus helps in normal functioning of insulin production and secretion.
- Among regions, North America is estimated to account for the largest market share in the global congenital hyperinsulinism treatment market over the forecast period, owing to the increasing research and development for the congenital hyperinsulinism by the key players in that region. For instance, in February 2021, Crinetics Pharmaceuticals, Inc., a pharmaceutical company based in the U.S., announced that it would receive up to approximately US$ 0.9 million in continued funding under its Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney diseases (NIDDK) of the National Institutes of Health (NIH). The funds are being used to support the ongoing research and development of nonpeptide somatostatin agonists for congenital hyperinsulinism (CHI) develop by Crinetics. In total, the company has been awarded approximately US$ 2.2 million in funding from the NIDDK under award number R44DK115290.
- Major players operating in the global congenital hyperinsulinism treatment market include Zealand Pharma A/S, Eli Lilly and Company, Xeris Pharmaceuticals, Inc., Rezolute, Inc., Hanmi Pharm.Co., Ltd., Fresenius Kabi AG, Eiger BioPharmaceuticals., Crinetics Pharmaceuticals, Inc., AmideBio,LLC, Jolly Healthcare, e5 Pharma,LLC, Merck & Co.,Inc., Novo Nordisk A/S, Amphaster Pharmaceuticals,Inc., USV Private Limited, Teva Pharmaceutical Industries Ltd.
